Phase II Study of XELOX and Cetuximab as First Line Therapy in Patients with Wild Type KRAS Metastatic Colorectal Cancer
Ontology highlight
ABSTRACT: Interventions: Capecitabine+oxaliplatin(XELOX)+Cetuximab Cetuximab loading dose 400mg/m2, 250mg/m2/week or 500mg/m2/2weeks Capecitabine 2000mg/m2(day1-7)/2weeks
Primary outcome(s): Response Rate
Study Design: Single arm Non-randomized
DISEASE(S): Metastatic Colorectal Cancer
PROVIDER: 2622614 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA